Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIDAH: Calcifediol in PAH
NCT06258850Phase 4Not yet recruiting
- Sponsor
- Parc de Salut Mar
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, randomised, triple-blind trial in pulmonary arterial hypertension (PAH) comparing Calcifediol with Placebo (2 arms). Primary endpoint: Clinical improvement without clinical worsening at 24 weeks. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
calcifediol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06258850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258850.